Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN 株式レポート

時価総額：US$253.9m

Eledon Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Eledon Pharmaceuticalsの CEO はDA Grosで、 Sep2020年に任命され、 の在任期間は 4.17年です。 の年間総報酬は$ 2.55Mで、 21.9%給与と78.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.015%を直接所有しており、その価値は$ 38.26K 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と5.9年です。

主要情報

DA Gros

最高経営責任者

US$2.6m

報酬総額

CEO給与比率21.9%
CEO在任期間4.2yrs
CEOの所有権0.02%
経営陣の平均在職期間3.6yrs
取締役会の平均在任期間5.9yrs

経営陣の近況

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

CEO報酬分析

Eledon Pharmaceuticals の収益と比較して、DA Gros の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$25m

Jun 30 2024n/an/a

-US$89m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$3mUS$559k

-US$117m

Sep 30 2023n/an/a

-US$145m

Jun 30 2023n/an/a

-US$145m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$1mUS$533k

-US$88m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$748kUS$504k

-US$35m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$7mUS$150k

-US$23m

報酬と市場: DAの 総報酬 ($USD 2.55M ) は、 US市場 ($USD 1.46M ) の同規模の企業の平均を上回っています。

報酬と収益: DAの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

DA Gros (52 yo)

4.2yrs

在職期間

US$2,553,153

報酬

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
David-Alexandre Gros
CEO & Non Independent Director4.2yrsUS$2.55m0.015%
$ 38.3k
Steven Perrin
President4.2yrsUS$1.54m0.0017%
$ 4.2k
Paul Little
Chief Financial Officer3.7yrsUS$1.32m0.017%
$ 42.5k
John Herberger
Vice President of Technical Operations2.5yrsデータなしデータなし
Bryan Smith
General Counsel3.6yrsUS$1.68m0%
$ 0
David Hovland
Chief Regulatory Officer3.6yrsデータなしデータなし
Eliezer Katz
Chief Medical Officer1.1yrsデータなしデータなし

3.6yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: ELDNの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
David-Alexandre Gros
CEO & Non Independent Director4.2yrsUS$2.55m0.015%
$ 38.3k
Steven Perrin
President4.2yrsUS$1.54m0.0017%
$ 4.2k
Keith Katkin
Independent Chairman of the Board7.5yrsUS$1.52m0.0011%
$ 2.9k
John McBride
Independent Director7.5yrsUS$371.82k0%
$ 0
James Robinson
Independent Director1.1yrsUS$201.79kデータなし
June Lee
Independent Director3.9yrsUS$374.44k0%
$ 0
Hamid Djalilian
Member of Scientific Advisory Board5.9yrsデータなしデータなし
Paola Marchisio
Member of Scientific Advisory Board5.9yrsデータなしデータなし
Tal Marom
Member of Scientific Advisory Board5.9yrsデータなしデータなし
Michael Pichichero
Member of Scientific Advisory Board5.9yrsデータなしデータなし
Anne Schilder
Member of Scientific Advisory Board5.9yrsデータなしデータなし
Seth Pranksy
Member of Scientific Advisory Board5.9yrsデータなしデータなし

5.9yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: ELDNの 取締役会 は 経験豊富 であると考えられます ( 5.9年の平均在任期間)。